KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Current Liabilities (2016 - 2025)

Travere Therapeutics' Total Current Liabilities history spans 14 years, with the latest figure at $159.9 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 20.35% year-over-year to $159.9 million; the TTM value through Dec 2025 reached $159.9 million, down 20.35%, while the annual FY2025 figure was $159.9 million, 20.35% down from the prior year.
  • Total Current Liabilities reached $159.9 million in Q4 2025 per TVTX's latest filing, up from $135.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $200.8 million in Q4 2024 to a low of $85.0 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $143.6 million, with a median of $135.4 million recorded in 2023.
  • The largest YoY upside for Total Current Liabilities was 56.3% in 2025 against a maximum downside of 28.92% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $124.1 million in 2021, then increased by 14.57% to $142.2 million in 2022, then increased by 25.14% to $177.9 million in 2023, then rose by 12.84% to $200.8 million in 2024, then fell by 20.35% to $159.9 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Total Current Liabilities are $159.9 million (Q4 2025), $135.1 million (Q3 2025), and $189.5 million (Q2 2025).